

ASX Release

SUDA LTD ESTABLISHES CLINICAL ADVISORY BOARD FOR SUD-003 ERECTILE DYSFUNCTION ORAL SPRAY

PERTH, AUSTRALIA – 25 June 2015: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces the appointment of three leading erectile dysfunction specialists to its Clinical Advisory Board (CAB) for SUD-003, the Company's first-in-class oral spray of sildenafil citrate for the treatment of erectile dysfunction. These experts are providing advice and guidance to SUDA on the pivotal development plan, which will be presented to the US FDA. The three appointments to the CAB are Dr William E Pullman, Dr David J Ralph and Associate Professor Eric Chung.

Dr Pullman is a physician with over 25 years' global experience matured in both large and small pharmaceutical companies, handling small molecules and biotechnology products across all phases of drug development. His industrial positions included Pfizer, Eli Lilly and Sanofi-Aventis where he set strategies and executed operational plans; managed drug discovery and development; supported regulatory approval and commercialisation of many drugs. He has co-authored several scientific papers and contributed to numerous abstracts and presentations for several International Societies. He is a Fellow of the Royal Australian College of Physicians and a speaker in many R&D forums on topics ranging from biomarker development and validation through to clinical development strategies.

Associate Professor Eric Chung is a consultant urological surgeon working in Brisbane Australia and a certified Fellow of the Royal Australasian College of Surgeons (RACS) and Urological Society of Australia and New Zealand (USANZ). He is the current Chair of the Andrology Group in USANZ and serves on many national advisory committees and international organisations. His main areas of interest are urinary dysfunction and reconstructive prosthesis, as well as male sexual and reproductive surgery. He actively runs several Phase 2 and 3 clinical trials, publishes extensively in peer-reviewed journals and book chapters, and has been invited to speak at many national and international meetings.

Dr Ralph is an internationally recognised urological microsurgeon and an Honorary Senior Lecturer at the Institute of Urology and Nephrology, University College London. He also teaches at the Royal College of Surgeons Microsurgery for Andrologists. His main areas of expertise are penile implants, total genital reconstruction, Peyronies disease and male infertility. He is the chairman of the Steering Group, Erectile Dysfunction Alliance, part of the Board of Trustees of the Sexual Dysfunction Association and part of the Nominating

Committee of the European Society for Impotence Research. Dr Ralph has published extensively, contributing to book chapters and scientific papers, and regularly speaks at international events.

SUDA's CEO, Mr Stephen Carter, commented: "We are thrilled to have attracted three of the world's leading experts with unparalleled clinical and medical experience in erectile dysfunction to advise SUDA on the development of SUD-003. The involvement of these key opinion leaders provides further endorsement of the merits of our unique oral spray formulation of sildenafil citrate for erectile dysfunction and will also support our objective to out-license the product to pharmaceutical companies."



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au

About SUD-003

SUD-003 is a first-in-class oro-mucosal spray formulation of sildenafil citrate (marketed in tablet form by Pfizer, Inc. under the brand name Viagra®) for the treatment of erectile dysfunction (ED). DuroMist™ is a metered spray that offers the potential for quicker onset of action, patient convenience, reduced food effect and lower dose. DuroMist™ has been evaluated in a pilot pharmacokinetic clinical study comparing the oral spray to the sildenafil tablet. The data suggest effective absorption via the oral transmucosal route and demonstrated an excellent safety profile at all dose levels. SUDA has recently completed development of a second-generation formulation with enhanced permeation characteristics that shows more efficient absorption than the original formulation. SUDA aims to meet with the FDA in H2 CY2015 to discuss the pivotal development plan for SUD-003.